New daily drug may offer alternative for those who cannot use CPAP machines

A new once-daily medication, AD109, demonstrated effectiveness in treating obstructive sleep apnea (OSA) during Phase 3 clinical trials. The drug reduces the frequency of breathing pauses and sleep-related oxygen deprivation, offering a potential alternative for patients who cannot tolerate standard CPAP therapy. The SynAIRgy study, published in the American Journal of Respiratory and Critical Care Medicine, involved 646 adult volunteers from the United States and Canada with varying severity of OSA. All participants had either refused continuous positive airway pressure (CPAP) machines or failed to adapt to them. How AD109 Works AD109 combines two substances: aroxibutinin and atomoxetine. The drug targets neuromuscular mechanisms to maintain throat muscle tone, helping prevent the collapse of the airways during sleep.